Declan Coleman

Clinical trials are the foundation of medical innovation, yet historically, they have not fully represented all populations that may experience disease differently. This lack of inclusivity undermines scientific validity, compromises treatment safety and efficacy, exacerbates health disparities, and impose a significant burden on the U.S. economy. Despite regulatory efforts, significant gaps remain in the participation of racial and ethnic minorities, women, older adults, rural populations, and individuals with comorbidities.